Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash & Current Investments (2016 - 2026)

Voyager Therapeutics' Cash & Current Investments history spans 12 years, with the latest figure at $196.4 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 26.34% to $196.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $196.4 million, a 26.34% decrease, with the full-year FY2025 number at $196.4 million, down 26.34% from a year prior.
  • Cash & Current Investments hit $196.4 million in Q4 2025 for Voyager Therapeutics, down from $208.9 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for VYGR hit a ceiling of $399.6 million in Q1 2024 and a floor of $118.8 million in Q4 2022.
  • Historically, Cash & Current Investments has averaged $219.7 million across 5 years, with a median of $212.3 million in 2025.
  • Biggest five-year swings in Cash & Current Investments: soared 94.26% in 2023 and later crashed 41.89% in 2025.
  • Tracing VYGR's Cash & Current Investments over 5 years: stood at $132.5 million in 2021, then fell by 10.33% to $118.8 million in 2022, then soared by 94.26% to $230.9 million in 2023, then grew by 15.51% to $266.7 million in 2024, then fell by 26.34% to $196.4 million in 2025.
  • Business Quant data shows Cash & Current Investments for VYGR at $196.4 million in Q4 2025, $208.9 million in Q3 2025, and $215.6 million in Q2 2025.